PT  - JOURNAL ARTICLE
AU  - S Burkill
AU  - C M. Porsbjerg
AU  - A Bourdin
AU  - T N Tran
AU  - N Martin
AU  - R Katial
AU  - P Barker
AU  - M E Wechsler
AU  - J Maspero
AU  - S Bosnic-Anticevich
AU  - L P Chung
AU  - G Katsoulotos
AU  - G C Christoff
AU  - T A Popov
AU  - M Sadatsafavi
AU  - C A Torres-Duque
AU  - C Ulrik
AU  - K Dahl Assing
AU  - S Hansen
AU  - A Altraja
AU  - L A Lehtimaki
AU  - N G Papadopoulos
AU  - K Kostikas
AU  - S Salvi
AU  - R W Costello
AU  - P Francesca
AU  - T Iwanaga
AU  - C K Rhee
AU  - M Al-Ahmad
AU  - D Larenas-Linnemann
AU  - J A Fonseca
AU  - R Amaral
AU  - K Alving
AU  - R Al-Lehebi
AU  - L Perez De-Llano
AU  - B Kirenga
AU  - M Tsai
AU  - B Mahboub
AU  - P E Pfeffer
AU  - W Henley
AU  - Y Liu
AU  - J Lyu
AU  - C Goh
AU  - T Uthaman
AU  - D Price
AU  - J Townend
TI  - Real-life biomarker response to anti-IL5 and anti-IgE therapies in severe asthma patients
AID  - 10.1183/13993003.congress-2022.3305
DP  - 2022 Sep 04
TA  - European Respiratory Journal
PG  - 3305
VI  - 60
IP  - suppl 66
4099  - http://erj.ersjournals.com/content/60/suppl_66/3305.short
4100  - http://erj.ersjournals.com/content/60/suppl_66/3305.full
SO  - Eur Respir J2022 Sep 04; 60
AB  - Introduction/Background: Biologics (Bx) are known to decrease specific biomarker levels: anti-IL5 reduces blood eosinophils (BEC) and anti-IgE slightly reduces FeNO. Anti-IL5 and anti-IgE are thought to have limited effect on total IgE (IgE).Aims and Objectives: To assess the proportions of severe asthma patients whose biomarkers (BEC, FeNO, and serum IgE) decrease following anti-IL5 and anti-IgE initiation.Methods: Patients in the International Severe Asthma Registry (ISAR) with biomarker and Bx data were included. From pre-Bx baseline to the post-Bx time period, the median (IQR) change in biomarker level and the proportion of patients with >25% decrease in biomarkers were determined.Results: At 2-3 years from Bx initiation, BEC decreased by >25% in 80.7% of anti-IL5 and 41.6% of anti-IgE patients. FeNO decreased by >25% in 41.6% of anti-IL5 and 47.8% of anti-IgE patients. IgE decreased by >25% in 41.7% of anti-IL5 and 15.6% of anti-IgE patients (Figure).Figure: Median (IQR) biomarker changes and patient proportions with decreased biomarkers in response to Bx.Conclusions: Anti-IL5 was superior in decreasing BEC and both Bx classes decreased FeNO to a limited extent. The lower proportion of anti-IgE patients with IgE reduction could be attributed to serum total IgE (not free IgE) measurement. Apart from anti-IL5’s effect on BEC, <50% patients had decreased biomarkers; the clinical implications should be explored.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 3305.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).